The pathophysiological significance of proteases in patients with chronic inflammatory joint disease

蛋白酶在慢性炎症性关节病患者中的病理生理意义

基本信息

  • 批准号:
    12671421
  • 负责人:
  • 金额:
    $ 1.92万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2000
  • 资助国家:
    日本
  • 起止时间:
    2000 至 2001
  • 项目状态:
    已结题

项目摘要

To clarify the pathophysiological significance of proteases in RA and OA, we investigated what kinds of proteases were specifically activated in both synovial fluid and synovial tissue of RA & OA patients , and effects of serine proteases on release of inflammatory cytokines from synovial cells.We obtained the following fmdings. (I) When the protease substrates were incubated with SF supernatants, thrombin was the most preferentially hydrolyzed while trypsin substrate and cathepsin B substrate were hydrolyzed to some degree. In the case of SF cell extracts, cathepsin B substrate was the most preferentially hydrolyzed while the other substrates were hardly hydrolyzed. In the case of synovial tissue extracts, cathepsin B substrate was the most preferentially hydrolyzed while trypsin substrate was hydrolyzed to some degree. Protease activities were in general significantly higher in RA than in OA. (II) Thrombin (0.1 to 100 units /ml) significantly enhanced growth of the synovial fibroblast-like cells (FC). When SFC were cultured with thrombin (100 units/ml) or MCT (10 ng/ml), concentrations of IL-8 and IL-6 in the culture medium were significantly increased compared with the control, while the concentrations of IL-1□, IL-1□ and TNF-□ were not detectable in all the culture mediums. (III) Cathepsin B-like protease purified from both the SF and synovial tissues ofRA patients was mainly composed of cathepsin B, and the cathepsin B purified from SF samples ofRA patients was capable of activating prourokinase to urokinase in vitro.
为了阐明蛋白酶在RA和OA中的病理生理意义,我们研究了RA和OA患者滑液和滑膜组织中哪些蛋白酶被特异性激活,以及丝氨酸蛋白酶对滑膜细胞释放炎性细胞因子的影响。(I)当蛋白酶底物与SF上清液孵育时,凝血酶最优先水解,而胰蛋白酶底物和组织蛋白酶B底物在一定程度上被水解。对于SF细胞提取物,组织蛋白酶B底物最优先水解,而其他底物几乎不水解。在滑膜组织提取物的情况下,组织蛋白酶B底物最优先水解,而胰蛋白酶底物在一定程度上水解。蛋白酶活性在一般显着高于RA比OA。(II)凝血酶(0.1至100单位/ml)显着增强滑膜成纤维细胞样细胞(FC)的生长。当SFC与凝血酶(100 units/ml)或MCT(10 ng/ml)共同培养时,培养液中IL-8和IL-6的浓度较对照组显著升高,而IL-1□、IL-1□和TNF-□在所有培养液中均未检测到。(III)从RA患者滑液和滑液中分离纯化的类组织蛋白酶B主要由组织蛋白酶B组成,且从RA患者滑液中分离纯化的组织蛋白酶B在体外可激活尿激酶原为尿激酶。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Ikeda Y, et al.: "Cathepsin B and L in synovial fluids from patients with rheumatoid arthritis and the effect of cathepsin B on the activation of pro-urokinase"The Journal of Medical Investigation. 47. 61-75 (2000)
Ikeda Y等人:“类风湿性关节炎患者滑液中的组织蛋白酶B和L以及组织蛋白酶B对尿激酶原激活的影响”医学调查杂志。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Takeda Y. et al.: "The most effective exercise for strengthening the supraspinatus : evaluation by magnetic resonance imaging"American Journal of Sports Medicine. (In press). (2002)
Takeda Y.等人:“增强冈上肌最有效的运动:磁共振成像评估”美国运动医学杂志。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
中野俊次 他: "慢性関節リウマチにおけるカテプシンBとトロンビンの関与."日本整形外科学会雑誌. 74巻. S1743 (2000)
Shunji Nakano 等人:“组织蛋白酶 B 和凝血酶在类风湿性关节炎中的作用。”日本骨科学会杂志第 74 卷(2000 年)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
S.Nakano, et al: "Activity of cathepsin B and thrombin in rhumatoid arthritis"Transactious of 47th Annual Meeting ORS. (2001)
S.Nakano等人:“组织蛋白酶B和凝血酶在类风湿性关节炎中的活性”第47届ORS年会的交易。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Takeda Y, et al.: "The most effective exercise for strengthening the supraspinatus : evaluation by magnetic resonance imaging"American Journal of Sports Medicine.. (in press). (2002)
Takeda Y 等人:“增强冈上肌最有效的运动:磁共振成像评估”美国运动医学杂志(正在出版)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NAKANO Shunji其他文献

NAKANO Shunji的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NAKANO Shunji', 18)}}的其他基金

Establishment of bilateral asymmetry through selective segregatin of sister chromatids
通过姐妹染色单体的选择性分离建立双侧不对称
  • 批准号:
    24770204
  • 财政年份:
    2012
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Thrombin and mast cell tryptase are trigger proteases in arthritis.
凝血酶和肥大细胞类胰蛋白酶是关节炎的触发蛋白酶。
  • 批准号:
    17591577
  • 财政年份:
    2005
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the pathophysiological significance of mast cell tryptase and protease activated receptor-2 (PAR-2) in articular destruction
阐明肥大细胞类胰蛋白酶和蛋白酶激活受体 2 (PAR-2) 在关节破坏中的病理生理学意义
  • 批准号:
    15591581
  • 财政年份:
    2003
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
  • 批准号:
    31070748
  • 批准年份:
    2010
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目

相似海外基金

Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
  • 批准号:
    MR/Y009681/1
  • 财政年份:
    2024
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
  • 批准号:
    MR/Y022947/1
  • 财政年份:
    2024
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Research Grant
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
  • 批准号:
    491810
  • 财政年份:
    2023
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Operating Grants
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
  • 批准号:
    EP/Y027760/1
  • 财政年份:
    2023
  • 资助金额:
    $ 1.92万
  • 项目类别:
    Fellowship
The roles and mechanisms of inflammation resolution in the development of Rheumatoid Arthritis
炎症消退在类风湿关节炎发展中的作用和机制
  • 批准号:
    10733789
  • 财政年份:
    2023
  • 资助金额:
    $ 1.92万
  • 项目类别:
Microbial metabolites impacting the response to methotrexate in rheumatoid arthritis
微生物代谢物影响类风湿性关节炎对甲氨蝶呤的反应
  • 批准号:
    10578433
  • 财政年份:
    2023
  • 资助金额:
    $ 1.92万
  • 项目类别:
Novel first-in-class Therapeutics for Rheumatoid Arthritis
类风湿关节炎的一流新疗法
  • 批准号:
    10696749
  • 财政年份:
    2023
  • 资助金额:
    $ 1.92万
  • 项目类别:
A Potent D-peptide Inhibitor of TNFα for Treatment of Rheumatoid Arthritis
一种有效的 TNFα D 肽抑制剂,用于治疗类风湿性关节炎
  • 批准号:
    10822182
  • 财政年份:
    2023
  • 资助金额:
    $ 1.92万
  • 项目类别:
Fibroblast-mediated inflammatory resolution of rheumatoid arthritis
成纤维细胞介导的类风湿性关节炎炎症消退
  • 批准号:
    10604629
  • 财政年份:
    2023
  • 资助金额:
    $ 1.92万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了